HomeCompareKCDMF vs PFE

KCDMF vs PFE: Dividend Comparison 2026

KCDMF yields 5.86% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KCDMF wins by $56.5K in total portfolio value
10 years
KCDMF
KCDMF
● Live price
5.86%
Share price
$2.22
Annual div
$0.13
5Y div CAGR
28.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$106.1K
Annual income
$29,037.46
Full KCDMF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — KCDMF vs PFE

📍 KCDMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKCDMFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KCDMF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KCDMF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KCDMF
Annual income on $10K today (after 15% tax)
$497.75/yr
After 10yr DRIP, annual income (after tax)
$24,681.84/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, KCDMF beats the other by $2,361.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KCDMF + PFE for your $10,000?

KCDMF: 50%PFE: 50%
100% PFE50/50100% KCDMF
Portfolio after 10yr
$77.8K
Annual income
$27,648.09/yr
Blended yield
35.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

KCDMF
No analyst data
Altman Z
4.4
Piotroski
9/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KCDMF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKCDMFPFE
Forward yield5.86%6.13%
Annual dividend / share$0.13$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR28.9%13.2%
Portfolio after 10y$106.1K$49.6K
Annual income after 10y$29,037.46$26,258.71
Total dividends collected$76.3K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KCDMF vs PFE ($10,000, DRIP)

YearKCDMF PortfolioKCDMF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,455$754.82$9,153$693.39+$2.3KKCDMF
2$13,298$1,041.60$8,593$849.25+$4.7KKCDMF
3$15,686$1,456.72$8,336$1,066.78+$7.3KKCDMF
4$18,854$2,069.95$8,437$1,384.80+$10.4KKCDMF
5$23,171$2,997.22$9,013$1,875.40+$14.2KKCDMF
6$29,230$4,437.41$10,306$2,680.72+$18.9KKCDMF
7$38,020$6,743.56$12,820$4,101.38+$25.2KKCDMF
8$51,248$10,566.66$17,673$6,826.70+$33.6KKCDMF
9$71,993$17,158.23$27,543$12,591.86+$44.5KKCDMF
10$106,070$29,037.46$49,560$26,258.71+$56.5KKCDMF

KCDMF vs PFE: Complete Analysis 2026

KCDMFStock

Kimberly-Clark de México, S. A. B. de C. V., together with its subsidiaries, manufactures and commercializes disposable products for daily use by consumers in Mexico. The company offers diapers, pull-up training pants, swim diapers, wet wipes, shampoos, cream and bar soaps, and feeding products for babies; beauty products, including bar soaps, liquid hand soaps, foaming liquid soaps, liquid body washes, micellar water, and makeup removing wipes; and underwear, protectors, feminine pads, and prefolded products for adults. It also provides toilet paper, napkins, facial tissues, and paper towels for home; feminine pads, panty liners, tampons, and intimate wipes for women; and dispensers, jumbo roll toilet papers, paper towels, hand towels, anti-bacterial gel, disinfecting spray, facemasks, and industrial cleaning cloths for professional use. The company offers its products primarily under the Huggies, KleenBebe, Pull-Ups, Evenflo, Kleenex, Kotex, Depend, Cottonelle, Pétalo, Suavel, Vogue, Sanitas, Marli y Kimlark, Jabón Escudo Antibacterial, and Jabones Kleenex brands. The company also exports its products. Kimberly-Clark de México, S. A. B. de C. V. was founded in 1925 and is based in Mexico City, Mexico.

Full KCDMF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this KCDMF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KCDMF vs SCHDKCDMF vs JEPIKCDMF vs OKCDMF vs KOKCDMF vs MAINKCDMF vs JNJKCDMF vs MRKKCDMF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.